Relmada Therapeutics(RLMD) - 2021 Q2 - Quarterly Report
Relmada Therapeutics(RLMD)2021-08-10 20:03UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Exact name of registrant as specified in its charter) | Nevada | 45-5401931 | | --- | --- | | (State or Other Jurisdiction of | (I.R.S. Employer | FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ ...